| Original language | English (US) |
|---|---|
| Pages (from-to) | 12-15 |
| Number of pages | 4 |
| Journal | Gynecologic oncology |
| Volume | 158 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jul 2020 |
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynecology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Gynecologic oncology, Vol. 158, No. 1, 07.2020, p. 12-15.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - The 2020 SGO Annual Meeting Report
AU - Kim, Kenneth H.
AU - Moore, Kathleen N.
AU - Arend, Rebecca C.
AU - Bakkum-Gamez, Jamie N.
AU - Westin, Shannon N.
N1 - Funding Information: Dr. Kenneth Kim reports educational grants from Intuitive Surgical and consulting fees from Johnson & Johnson, outside the submitted work. Dr. Kathleen Moore reports personal fees and other from Astra Zeneca; grants, personal fees and other from Genentech/Roche; grants, personal fees and other from Immunogen; grants, personal fees and other from Clovis; grants, personal fees and other from Tesaro; personal fees and other from Pfizer; personal fees from Janssen, personal fees from Aravive; personal fees from VBL Therapeutics; personal fees and other from Onco Med; personal fees from Samumed; grants and other from Lilly; personal fees from Eisai; personal fees from Vavotar; personal fees from Abbvie; personal fees from Tarveda; outside the submitted work. Dr. Rebecca Arend reports serving on advisory boards for AstraZeneca, Clovis, and LEAP Therapeutics and serving on steering committees for VBL Therapeutics and Merck, outside the submitted work. Dr. Jamie Bakkum-Gamez reports grants from NIH, V Foundation, and joint intellectual property ownership from Exact Sciences, outside the submitted work. Dr. Shannon Westin reports grants from the NIH and the GOG Foundation, grants and personal fees from AstraZeneca, Clovis, GlaxoSmithKline/Tesaro, Roche/Genentech, Novartis, personal fees from Merck, Pfizer, Eisai, and Circulogene, as well as grants from Cotinga Pharmaceuticals, Bayer, and ArQule, outside the submitted work.
PY - 2020/7
Y1 - 2020/7
UR - http://www.scopus.com/inward/record.url?scp=85085619640&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085619640&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2020.05.031
DO - 10.1016/j.ygyno.2020.05.031
M3 - Article
C2 - 32487447
AN - SCOPUS:85085619640
SN - 0090-8258
VL - 158
SP - 12
EP - 15
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 1
ER -